From mouth to muscle: mechanistic and interventional perspectives on the tongue-coating microbiome in sarcopenia

<h4>Background</h4>Sarcopenia, the progressive loss of skeletal muscle mass and function, needs upstream, low-burden tools for early detection and high-frequency monitoring, especially in older adults. Conventional assessments such as handgrip strength and gait speed mainly capture downstream impairment and may miss early physiological change. The tongue-coating microbiome is an emerging, measurable niche on the oral-gut-muscle axis that may provide proximal signals of metabolic, inflammatory, and circadian status.<h4>Methods</h4>We performed a narrative summary of recent evidence on tongue-gut coupling, mapped plausible mechanisms to muscle regulation, and evaluated the feasibility of tongue-based measurement. We propose a minimal methods set (fixed pre-breakfast sampling, strict low-biomass quality control, AI-assisted standardized tongue imaging, saliva assays integrated with multi-omics) and a three-tier metric structure aligned to the minimal clinically important difference (MCID) for functional endpoints.<h4>Results</h4>Evidence supports links across three axes: metabolic (microbial metabolites such as short-chain fatty acids and niacin that modulate mitochondrial energetics and anabolism), inflammatory (oral dysbiosis and barrier disruption amplifying systemic inflammation via lipopolysaccharide, Toll-like receptor 4, and NF-κB signaling), and circadian (microbiome rhythms coupled to eating and sleep timing). The tongue coating forms a stable niche suitable for frequent follow-up. An upstream-midstream-downstream metric stack enables MCID-anchored interpretation. Current data are limited and heterogeneous, so tongue-derived metrics should complement stool testing and functional standards.<h4>Conclusions</h4>Tongue-based monitoring is a practical adjunct for earlier risk signaling and community-level follow-up. Priorities are multicenter validation, interpretable and device agnostic models, and axis-stratified trials to define when and for whom tongue-derived signals add MCID-level clinical value. Because direct longitudinal human evidence linking tongue-coating signals to clinically meaningful sarcopenia outcomes remains limited, we frame the tongue-coating microbiome primarily as a hypothesis-driven, upstream monitoring niche and outline testable priorities for validation and translation.